| Name | Title | Contact Details |
|---|
Dewpoint Therapeutics is leveraging a transformative shift in the understanding of cellular biology regulation to discover and advance breakthrough small-molecule therapeutics.
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
Apeel Sciences creates products from natural plant extracts that allow growers to reduce reliance on pesticides, increase produce quality, and provide superior shelf life without refrigeration.
BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.
LifeSpan Biosciences is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.